使用临床暴露的定量测量来描述不确定的药物耐药性 (VUDRs) 的变种
Haider Inam1,2, Marta Tomaszkiewicz1,3, Joshua Reynolds1,3
1Department of Biomedical Engineering, 211 Wartik Lab, The Pennsylvania State University, University Park, PA 16802, USA.
bioRxiv : the preprint server for biology
|November 24, 2025
概括
许多癌症抗药性变体缺乏表征. 本研究介绍了一种方法来分类这些不确定的药物耐药性变体 (VUDRs),可能指导治疗并降低成本.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 瘤基因的体质突变可能导致抗癌药物耐药性.
- 许多这样的变体在临床上没有特征,被称为不确定的耐药性变体 (VUDRs).
- 对VUDR缺乏功能性注释,这阻碍了临床管理.
研究的目的:
- 开发一个高通量平台,用于分类耐药性变体.
- 评估VUDRs对伊马替尼治疗的临床影响.
- 建立一个可通用的框架来对抗性变体进行分类.
主要方法:
- 使用深度突变扫描分析了4922种对伊马替尼布耐药性的变体.
- 定量度-反应测量与人类的药理动力学数据有关.
- 用了18个标准来验证药物敏感性的两个数量级的性能.
主要成果:
- 该平台表现出强大的定量性能和临床一致性.
- 超过10%的分析的临床VUDRs产生了适度的耐药性,可能通过剂量升级来控制.
- 确定了祖先特定的变体,表明了私人VUDRs的潜力.
结论:
- 建立了一个与人类剂量相关的药物耐药性变体高通量分类的新框架.
- 研究结果表明,用通用伊马替尼布剂量升级可以克服适度的耐药性,从而可能降低财务毒性.
- 该研究强调了为个性化癌症治疗特征VUDRs的重要性.
相关概念视频
Drug Concentrations: Measurements
1.0K
Drug concentration is the quantity of a drug present in a biological sample. Measuring drug amounts in biological samples allows the clinician to understand how a drug is absorbed, distributed, metabolized, and excreted. Samples can be obtained through invasive or non-invasive methods. Invasive techniques involve surgical or parenteral interventions to gather blood, cerebrospinal fluid, or tissue biopsy. Conversely, non-invasive approaches provide samples like urine, feces, and saliva.
Plasma...
Plasma...
1.0K
Measurement of Bioavailability: Pharmacokinetic Methods
247
Pharmacokinetics is a vital branch of pharmacology that examines how drugs are absorbed, distributed, metabolized, and excreted by the body. Two key methodologies in pharmacokinetics are plasma drug concentration studies and urinary drug excretion analyses, both of which provide critical insights into a drug's therapeutic efficacy and bioavailability.Plasma Drug Concentration-Time StudiesPlasma drug concentration-time studies involve analyzing blood samples at specific intervals to quantify...
247
Measurement of Bioavailability: Pharmacodynamic Methods
221
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
221
Quantitative Aspects of Drug-Receptor Interaction
1.7K
The receptor occupancy theory connects a drug's response to the number of occupied receptors. With higher drug concentrations, more receptors are occupied, leading to increased responses. The formation of drug-receptor complexes involves association and dissociation rates, which reach equilibrium when the forward and backward reactions are equal. The equilibrium association constant (Ka) and its inverse, the equilibrium dissociation constant (Kd), indicate drug affinity. Higher Ka and lower...
1.7K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
387
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
387
Dosage Regimens: Partial Pharmacokinetic Parameters
138
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
138


